(Photo credit: Destiny Pharma www.destinypharma.com) 
Researchers at UK’s Destiny Pharma believe they have developed a drug which can destroy the most virulent strains of MRSA.  They are testing the drug code named XF-73 in the hope it can be used in hospitals by 2011.
Study results of the new drug, which is applied as a gel into patients’ noses, showed methicillin-resistant Staphylococcus aureus bacteria (MRSA) did not develop resistance to the compound despite being exposed to it 55 times.
Elaine Warburton  www.geneticsandhealth.com